Zimmer will spin off says Bristol-Myers Squibb:
This article was originally published in Clinica
Executive Summary
After some months of wavering between a sale or flotation for its Zimmer orthopaedics business, Bristol-Myers Squibb has decided on an IPO. Although both Swiss company Sulzer Medica and UK company Smith & Nephew announced interest, it was widely thought that the tax implications of a sale meant that a spin-off was the more attractive option. It is not yet known how much of Zimmer will be offered for sale or what value Bristol places on the company.